Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int J Clin Pract ; 75(8): e14347, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33977587

ABSTRACT

AIMS: To test the hypothesis of a semi-supervised home physical exercise programme that is likely to improve the functional mobility and quality of life (QOL) of elderly in the community. METHODS: This trial included elderly adults (88% female) aged 60 years or older and who were sedentary and without cognitive decline. The participants were randomly assigned to an intervention group (IG, home physical exercise and sleep hygiene) and a control group (CG, sleep hygiene). The International Questionnaire on Physical Activity, mental state mini-exam, World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) and the Timed Up and Go (TUG) tests were conducted before and after the 12-week intervention period. RESULTS: The study was concluded with 125 elderly participants. Anthropometric data were indicative of pre-obesity, with a mean body mass index of 27.3 ± 4, a low-income socio-economic profile (78% ≤ 2 SM) and low schooling rates (76% ≤ 3 years of study). Most of the elderly (87%) were considered physically active with IPAQ > 150 min/week. The group of elderly people who performed the home physical exercise programme showed a significant improvement in functional mobility according to the time of execution of the TUG test before (9.1 ± 2) and after (7.1 ± 1) with an average reduction of 2 ± 1 s (P < .01). The difference in the QOL of the elderly who participated in the exercise protocol was also observed, verified through the WHOQOL-OLD global score, which presented an initial score of 85 ± 10, changing to 90.4 ± 9 after the intervention. CONCLUSION: Semi-supervised physical home exercise is safe and effective in improving the functional mobility and QOL of sedentary elderly people in the community.


Subject(s)
Exercise , Quality of Life , Aged , Exercise Therapy , Female , Humans , Male , Prospective Studies , Surveys and Questionnaires
2.
J Bras Pneumol ; 34(7): 514-27, 2008 Jul.
Article in Portuguese | MEDLINE | ID: mdl-18695797

ABSTRACT

Alpha-1 antitrypsin deficiency is a recently identified genetic disease that occurs almost as frequently as cystic fibrosis. It is caused by various mutations in the SERPINA1 gene, and has numerous clinical implications. Alpha-1 antitrypsin is mainly produced in the liver and acts as an antiprotease. Its principal function is to inactivate neutrophil elastase, preventing tissue damage. The mutation most commonly associated with the clinical disease is the Z allele, which causes polymerization and accumulation within hepatocytes. The accumulation of and the consequent reduction in the serum levels of alpha-1 antitrypsin cause, respectively, liver and lung disease, the latter occurring mainly as early emphysema, predominantly in the lung bases. Diagnosis involves detection of low serum levels of alpha-1 antitrypsin as well as phenotypic confirmation. In addition to the standard treatment of chronic obstructive pulmonary disease, specific therapy consisting of infusion of purified alpha-1 antitrypsin is currently available. The clinical efficacy of this therapy, which appears to be safe, has yet to be definitively established, and its cost-effectiveness is also a controversial issue that is rarely addressed. Despite its importance, in Brazil, there are no epidemiological data on the prevalence of the disease or the frequency of occurrence of deficiency alleles. Underdiagnosis has also been a significant limitation to the study of the disease as well as to appropriate treatment of patients. It is hoped that the creation of the Alpha One International Registry will resolve these and other important issues.


Subject(s)
Pulmonary Disease, Chronic Obstructive/diagnosis , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/therapy , alpha 1-Antitrypsin/blood , Biomarkers/blood , Diagnosis, Differential , Humans , Liver Diseases/diagnosis , Phenotype , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Emphysema/diagnosis , Registries , alpha 1-Antitrypsin Deficiency/genetics
3.
J. bras. pneumol ; 34(7): 514-527, jul. 2008. ilus, tab
Article in English, Portuguese | LILACS | ID: lil-488278

ABSTRACT

A deficiência de alfa-1 antitripsina é um distúrbio genético de descoberta recente e que ocorre com freqüência comparável à da fibrose cística. Resulta de diferentes mutações no gene SERPINA1 e tem diversas implicações clínicas. A alfa-1 antitripsina é produzida principalmente no fígado e atua como uma antiprotease. Tem como principal função inativar a elastase neutrofílica, impedindo a ocorrência de dano tecidual. A mutação mais freqüentemente relacionada à doença clínica é o alelo Z, que determina polimerização e acúmulo dentro dos hepatócitos. O acúmulo e a conseqüente redução dos níveis séricos de alfa-1 antitripsina determinam, respectivamente, doença hepática e pulmonar, sendo que esta se manifesta principalmente sob a forma de enfisema de aparecimento precoce, habitualmente com predomínio basal. O diagnóstico envolve a detecção de níveis séricos reduzidos de alfa-1 antitripsina e a confirmação fenotípica. Além do tratamento usual para doença pulmonar obstrutiva crônica, existe atualmente uma terapia específica com infusão de concentrados de alfa-1 antitripsina. Essa terapia de reposição, aparentemente segura, ainda não teve a eficácia clínica definitivamente comprovada, e o custo-efetividade também é um tema controverso e ainda pouco abordado. Apesar da sua importância, não existem dados epidemiológicos brasileiros a respeito da prevalência da doença ou da freqüência de ocorrência dos alelos deficientes. O subdiagnóstico também tem sido uma importante limitação tanto para o estudo da doença quanto para o tratamento adequado dos pacientes. Espera-se que a criação do Registro Internacional de Alfa-1 venha a resolver essas e outras importantes questões.


Alpha-1 antitrypsin deficiency is a recently identified genetic disease that occurs almost as frequently as cystic fibrosis. It is caused by various mutations in the SERPINA1 gene, and has numerous clinical implications. Alpha-1 antitrypsin is mainly produced in the liver and acts as an antiprotease. Its principal function is to inactivate neutrophil elastase, preventing tissue damage. The mutation most commonly associated with the clinical disease is the Z allele, which causes polymerization and accumulation within hepatocytes. The accumulation of and the consequent reduction in the serum levels of alpha-1 antitrypsin cause, respectively, liver and lung disease, the latter occurring mainly as early emphysema, predominantly in the lung bases. Diagnosis involves detection of low serum levels of alpha-1 antitrypsin as well as phenotypic confirmation. In addition to the standard treatment of chronic obstructive pulmonary disease, specific therapy consisting of infusion of purified alpha-1 antitrypsin is currently available. The clinical efficacy of this therapy, which appears to be safe, has yet to be definitively established, and its cost-effectiveness is also a controversial issue that is rarely addressed. Despite its importance, in Brazil, there are no epidemiological data on the prevalence of the disease or the frequency of occurrence of deficiency alleles. Underdiagnosis has also been a significant limitation to the study of the disease as well as to appropriate treatment of patients. It is hoped that the creation of the Alpha One International Registry will resolve these and other important issues.


Subject(s)
Humans , Pulmonary Disease, Chronic Obstructive/diagnosis , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/therapy , alpha 1-Antitrypsin/blood , Biomarkers/blood , Diagnosis, Differential , Liver Diseases/diagnosis , Phenotype , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Emphysema/diagnosis , Registries , alpha 1-Antitrypsin Deficiency/genetics
4.
J. pneumol ; 26(6): 291-296, nov.-dez. 2000. tab, graf
Article in Portuguese | LILACS | ID: lil-339124

ABSTRACT

O abandono do tratamento da tuberculose tem implicações sociais e epidemiológicas. Objetivos: Comparar características de pacientes que abandonaram o tratamento com os que não o abandonaram (controle), matriculados no CS-EPM/Unifesp, no período de 1995 a 1997, e verificar se os grupos educativos de sala de espera diminuíram a ocorrência dos abandonos. Método: Foi realizado estudo retrospectivo controlado com 100 pacientes (38 abandonos pareados para 62 controles) matriculados para tratamento de tuberculose, em que se verificaram as variáveis mais relacionadas ao abandono. Destes, 60 pacientes participaram voluntariamente de grupos educativos (16 abandonos e 44 controles). Resultados: As variáveis mais relacionadas ao abandono foram: sexo masculino, tabagismo, alcoolismo, uso de drogas, presença de fatores de risco para HIV e internação prévia. Os que participaram voluntariamente dos grupos educativos de sala de espera tinham características semelhantes ao total de pacientes estudados, mas houve menor ocorrência de abandono durante o tratamento (p < 0,05). Conclusão: Os autores concluem que, tendo-se amplamente disponíveis os meios para diagnóstico e seguimento dos pacientes com tuberculose, todos os esforços possíveis deverão estar concentrados para evitar o abandono, sobretudo nos pacientes de risco, que deverão ter à sua disposição grupos educativos sobre a doença


Subject(s)
Humans , Male , Female , Patient Dropouts/statistics & numerical data , Health Education , Tuberculosis, Pulmonary/drug therapy , Case-Control Studies , Chi-Square Distribution , Odds Ratio , Surveys and Questionnaires , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...